×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!
   

Innovative Clinical Trial Designs — Welcomed By Regulators But What About The Payers?

April 25, 2018

There is a well-recognized long-standing decline in R&D productivity in the pharmaceutical industry which has driven exploration of new approaches to the clinical development of pharmaceuticals (Scannell, 2012). These include innovative randomized controlled trial designs, such as adaptive, umbrella, basket, and pragmatic studies.

There will be pragmatic attitudes amongst payers regarding the use of innovative clinical trial designs however there will also be skepticism; for many HTA bodies this is new and uncertain territory.

Previous Flipbook
Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article
Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article

Next Flipbook
Patient_Lay_Summaries_Framework_ISMPP_Poster_2017
Patient_Lay_Summaries_Framework_ISMPP_Poster_2017